Clinical Trial Update: Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating disitamab vedotin plus pyrotinib versus THP in first-line HER2-positive metastatic breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Disitamab Vedotin (disitamab vedotin)
• Pyrotinib (pyrotinib)
• THP

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: HER2-positive Metastatic Breast Cancer, First-line Treatment | Phase 3 | Status: RECRUITING